

November 22, 2017

**Notice Regarding 340B Pricing Through
Cardinal Health Specialty Pharmaceutical Distribution**

Johnson & Johnson Health Care Systems Inc., (JJHCS) on behalf of Johnson & Johnson companies participating in the 340B program (Janssen Pharmaceuticals, Inc., Janssen Biotech, Inc., Janssen Products LP, Patriot Pharmaceuticals LLC, and Scios, LLC.) (J&J Companies) has asked the Office of Pharmacy Affairs to post this notice on its public website to ensure transparency.

J&J Companies were recently informed that a sub-set of 340B customers may not have received 340B pricing on drugs distributed through Cardinal Health Specialty Pharmaceutical Distribution (CSPD) as listed below. It has always been and remains the intent of J&J Companies to make the 340B price available to all eligible customers through CSPD. In addition, it is our intention that any voluntarily offered subceiling pricing be extended consistent with our intentions.

JJHCS worked with CSPD to identify customers who did not receive appropriate 340B pricing. We requested that CSPD process credit-rebills for impacted transactions within the past 12 months and pass-through credits for impacted transactions prior to that time. We have been advised that CSPD has communicated with affected customers about the revised pricing and credits. We are providing this notice to the larger 340B community to ensure any customers not already identified are aware of the issue.

If you believe you have not received appropriate credits, please contact JJHCS at 732-562-3770.

NDC	Product Name
57894005427	STELARA (ustekinumub) 130 mg/26 ml vial
57894006002	STELARA (ustekinumub) 45mg/0.5ml vial
57894042001	SYLVANT (siltuximab) 100mg vial
57894042101	SYLVANT (siltuximab) 400mg vial
57894050205	DARZALEX (daratumumab) 100mg/5ml vial
57894050220	DARZALEX (daratumumab) 400mg/20ml vial
59676061001	YONDELIS (trabectedin) 1 mg vial